Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

2964 - MicroRNA as predictive biomarker of survival for stage IIIB colon cancer patients


08 Oct 2016


Poster Display


Pan Li


Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370


P. Li1, Q. Ou2, G. Chen2, F.S. Oduncu1

Author affiliations

  • 1 Oncology, Klinikum der Universität München, 80336 - München/DE
  • 2 Colorectal Surgery, Cancer Centre Sun Yat-Sen University, 510060 - Guangzhou/CN


Abstract 2964


The dismal outcome of stage IIIB colon cancer highlights the need for targeted therapies on the basis of effective predictive biomarkers, such as microRNA (miRNA).


Microarray was used to compare the miRNA expression profiles for 8 stage III B colon cancer patients with worse prognosis (metastases between 8 months and 18 months) and 8 cured stage III B colon cancer patients. Quantitative real-time polymerase chain reaction (qRT-PCR) analysis of the expression of targeted miRNAs was performed on tumor tissue of 98 patients with stage IIIB B colon cancer. A predictive model for 5-year disease-free survival (DFS) and overall survival (OS) was constructed using Kaplan–Meier analysis, logistic and Cox regression.


miRNA-192-3p and miRNA-192-5p were down regulated in group with worse prognosis (P = 0.026 and P = 0.042 respectively). Patients with higher expression of miRNA-192-5p had higher 5-year DFS (84.21%) and OS (89.47%) than those with lower targeted miRNA expression (DFS 38.8%, HR: 3.74, 95% confidence interval (CI): 1.52-9.23, P: 0.04; OS 48.57%, HR: 5.01, 95%CI: 1.75-14.38, P: 0.03). Patients with higher expression MiRNA-192-3p did not statistically impact the survival in this setting (DFS 73.33%vs64.7%, HR:0.68, 95%CI: 0.31-1.52, P:0.35; OS 76.67%vs66.17%, HR: 0.62, 95% CI: 0.27-1.45, P: 0.27).


MiRNA-192-5p is highly predictive marker for stage III B colon cancer patients. MiRNA-192-3p had no predictive value in this setting

Clinical trial identification

Legal entity responsible for the study

P. Li, Q. Ou, G. Chen, F.S. Oduncu


Sun Yat-sen University


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings